logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Dapagliflozin CAS 461432-26-8

Dapagliflozin CAS 461432-26-8

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 461432-26-8

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15 days

Payment Terms: T/T, L/C, D/A, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
461432-26-8
Appearance ::
White Powder
Molecular Formula::
C21H25ClO6
Molecular Weight::
408.873
EINECS NO::
639-683-0
MDL NO::
MFCD13182359
CAS NO::
461432-26-8
Appearance ::
White Powder
Molecular Formula::
C21H25ClO6
Molecular Weight::
408.873
EINECS NO::
639-683-0
MDL NO::
MFCD13182359
Dapagliflozin CAS 461432-26-8

Product Description:

Product Name: Dapagliflozin CAS NO:461432-26-8

 

 

 

 

 

 

 

 

 

Synonyms:

[14C]-Dapagliflozin;

D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-,(1S);

(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethy)tetrahydro-2H-pyran-3,4,5-triol;

 

 

 

 

 

 

 

 

 

Chemical & Physical Properties:

Appearance :white powder

Assay :≥99.0%

Density:1.349g/cm3

Boiling Point:609℃ at 760 mmHg

Flash Point:322.1℃

 

 

 

 

 

 

 

 

 

 

 

Dapagliflozin (ForxigaTM) is a new anti-diabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca. It was approved by the European Medicines Agency (EMA) on November 12, 2012. It is The first SGLT2 inhibitor approved to be marketed for the treatment of type 2 diabetes can be used as an important choice in the treatment of diabetes, and is suitable for use as an auxiliary diet and exercise to improve blood sugar control in adults with type 2 diabetes.

 

 

 

 

 

 

 

 

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

 

 

 

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.